Coya Therapeutics, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| COYA | TVGN | VYGR | ACIU | INMB | CABA | |
|---|---|---|---|---|---|---|
| Market cap | 72.25M | 95.87M | 115.23M | 227.69M | 41.18M | 240.75M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -1.6 | — | -1.5 | 3.8 | -3.1 | -1.2 |
| Price/book | 1.7 | -1.4 | 0.7 | 4.3 | 1.8 | 1.1 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −46.10% | −75.61% | −57.14% | −33.62% | −18.40% | −42.74% |
| Today | −0.96% | −3.38% | +2.19% | +9.57% | +0.76% | 0.00% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All COYA news ›Financial Analysis: Coya Therapeutics (COYA) vs. Its Peers
Posted by Defense World Staff on Oct 31st, 2026 Coya Therapeutics (NASDAQ:COYA – Get Free Report) is one of 844 public companies in the “Biotechnology” industry, but how does it weigh in compared to its competitors? We will compare Coya…
Coya Therapeutics to Present Neurofilament Light Chain (NfL) Biomarker Stratification Methodology in the ALSTARS Trial to Minimize the Impact of Heterogeneity in ALS Clinical Trials at the 2026 Annual NEALS Meeting
Coya is currently conducting the ALSTARS Trial, a Phase 2/3, randomized, multi-center, double-blind, placebo-controlled study to evaluate the efficacy and safety of COYA 302 for the treatment of ALS (ClinicalTrials.gov ID: NCT07161999 ).…
Coya Therapeutics reaches 120 patients in ALS trial
The primary endpoint measures ALSFRS-R total-score change from baseline to Week 24 compared with placebo. Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 5,…
Coya Therapeutics expects FTD trial to start in 2027
The planned Phase 2 trial of COYA 302 for frontotemporal dementia is now expected in 2027, as resources are prioritized for ALS development. Coya is prioritizing resources toward ongoing ALS development and timely ALSTARS milestones. Its…
Coya Therapeutics Announces Participation at Chardan's 10th Annual Healthcare Conference
Coya Therapeutics (COYA) will participate in a panel discussion at Chardan's 10th Annual Healthcare Conference on October 20 in New York. Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- stocktitan.net3
- defenseworld.net1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 4 articles, not a forecast.